Verification of doses to PTV and OAR and 2D dose distribution in IMRT for 8 accelerators in Henan province / 中华放射医学与防护杂志

ABSTRACT

Objective@#To use TLDs and radiochromic films to verify the prescribed doses to both planned target volume (PTV) and organ at risk (OAR) and the 2D dose distribution in IMRT.@*Methods@#Eight accelerators of different models were selected in Henan province. The polystyrene phantom provided by IAEA was scanned using CT scanners and then the scanned images were transmitted to treatment planning system (TPS) for prescribing respectively the doses to PTV and OAR. IMRT was performed with phantom exposed to a 6 MV X-rays. The irradiated TLDs and films were delivered for measurement and estimation at Secondary Standard Dosimetry Laboratory at National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention.@*Results@#According to IAEA requirements, the relative deviations of the TLD-measured and TPS-planned values were within ±7.0% for the prescribed doses to PTV and OAR. The measured results for PTV have shown that the relative deviation of TLD-measured and TPS-planned values were within -0.3% to 6.9% for 8 accelerators, all consistent with the IAEA requirements. For OAR, the relative deviations of TLD-measured and TPS-planned were within -7.0% to 0.3% for 6 accelerators, consistent with the requirements, whereas those for other 2 accelerators were within -10.8% to -8.4%, not up to the requirements. IAEA required that, for 2D dose distribution, the pass rate of 3 mm/3% be ≥90%. The measured values for 7 accelerators were from 90.2% to 99.9%, consistent with the requirements, whereas that for another one was 70.0%, not meeting the requirement.@*Conclusions@#The method to verify, using radiochromic film and TLD, the prescribed doses to PTV and OAR and the pass rate of 2D dose distribution is simple and reliable. It is an important step to implement quality control for IMRT and can provide effective support for medical or third-party service institution to verify clinically prescribed dose.